<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008110</url>
  </required_header>
  <id_info>
    <org_study_id>EC10-108</org_study_id>
    <secondary_id>2011-000414-20</secondary_id>
    <nct_id>NCT02008110</nct_id>
  </id_info>
  <brief_title>Carbohydrate Antigen 125-guided Therapy in Heart Failure</brief_title>
  <acronym>CHANCE-HF</acronym>
  <official_title>A Randomized Controlled Trial of Carbohydrate Antigen 125-guided Therapy Among Patients Recently Discharged for Acute Heart Failure: Effect on 1-year Mortality or Readmission for Acute Heart Failure (CHANCE-HF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary data suggest a potential role for monitoring and up-titrate pharmacological
      therapy of plasma levels of antigen carbohydrate 125 (CA125) following and admission for
      acute heart failure (AHF).

      This study will evaluate the effect of a CA125-guided management strategy versus standard
      therapy on the composite endpoint of 1-year all-cause mortality or readmission for AHF in
      patients recently discharged for AHF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause mortality plus acute heart failure related rehospitalization</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of total mortality plus readmission for any cause</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive outside of the hospital</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of heart failure rehospitalizations.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of worsening HF not requiring hospitalization</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CA125 guided strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapy is based on established european current guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA125 guided strategy</intervention_name>
    <description>Up titration of loop diuretics according to plasma levels of CA125 in the active arm</description>
    <arm_group_label>CA125 guided strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA125 guided strategy</intervention_name>
    <description>Consider statins in all patients in the active arm</description>
    <arm_group_label>CA125 guided strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA125 guided strategy</intervention_name>
    <description>Consider omega-3 polyunsaturated fatty acids in the active arm</description>
    <arm_group_label>CA125 guided strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CA125 guided strategy</intervention_name>
    <description>Frequency of monitoring according plasma evolution of CA125 in the active arm.</description>
    <arm_group_label>CA125 guided strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment strategy</intervention_name>
    <description>All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).</description>
    <arm_group_label>Standard treatment strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA125 guided strategy</intervention_name>
    <description>All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).</description>
    <arm_group_label>CA125 guided strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older.

          -  At least 1 admission for AHF, in the last 180 days.

          -  Demonstrates functional New York Heart Association status of Class ≥II at the moment
             of enrollment.

          -  Objective evidence, either during the index admission or at least 180 days before
             enrollment, of a structural or functional abnormality of the heart at rest, and
             defined as: N terminal-pro-brain natriuretic peptide &gt;1000 pg/ml or brain natriuretic
             peptide &gt;100 pg/ml or echocardiographic abnormalities congruent with HF diagnosis such
             as: systolic left ventricular dysfunction (LVEF &lt;50%); left ventricular hypertrophy
             (defined as left ventricular septum or left ventricular posterior wall thickness ≥12
             millimeters or left ventricular mass index &gt;104 g/m2 in women or 116 g/m2 in men);
             Ee`&gt;15 or significant valvular heart disease (moderate-severe).

          -  A plasma CA125 value &gt;35 U/ml in a recent test evaluation (at least 30 days before
             enrollment, and preferably assessed before hospital discharge).

          -  Patient must be capable of understanding and signing an informed consent form.

        Exclusion Criteria:

          -  Life expectancy &lt;12 months due to other diseases different from HF.

          -  Having undergone a cardiac transplantation, coronary revascularization procedure
             (percutaneous coronary intervention and/or coronary artery bypass grafting) or cardiac
             valve replacement in the past 3 months.

          -  Angina pectoris higher than class II (Canadian Cardiovascular Society Classification).

          -  Pregnancy at the moment of enrollment.

          -  Valvular heart disease already scheduled for surgical intervention.

          -  Severe chronic obstructive and/or restrictive pulmonary disease, requiring continuous
             oxygen administration.

          -  Serum creatinine level &gt; 3 mg/dl or chronic renal insufficiency on dialysis treatment.

          -  Patients receiving resynchronization therapy during the index admission.

          -  Significant concurrent medical diseases including cancer or a history of cancer within
             5 years of entering the screening period, endometriosis, cirrhosis, acute coronary
             syndrome within 6 months, uncontrolled hypertension, history of human immunodeficiency
             virus (HIV) infection, or a significant active infection.

          -  Participating in another randomized study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Núñez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Unbiversitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2013</study_first_submitted>
  <study_first_submitted_qc>December 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>Julio Nuñez</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Biomarker guided-therapy</keyword>
  <keyword>Carbohydrate antigen 125</keyword>
  <keyword>Clinical outcomes.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

